nach oben

Journal of Nephrology

Erschienen in:

01.08.2014 | Review

Skin cancer in kidney transplant recipients

verfasst von: Claudio Ponticelli, David Cucchiari, PierLuca Bencini

Erschienen in: Journal of Nephrology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Morbidity and mortality due to skin cancer is excessively high in renal transplant recipients compared to the general population. This epidemiologic difference is mainly due to the severe immunosuppression that enhances ultraviolet-induced DNA damage and leads to reactivation of potential oncogenic viruses. The most common skin cancer in transplant recipients is squamous cell carcinoma followed by basal cell carcinoma, while in the general population this ratio is reversed. Melanoma and cutaneous lymphoma are relatively rare although they occur more frequently in transplant patients than in the general population. Notably some tumors, such as Kaposi’s sarcoma, are seldom encountered in the general population while they are frequently observed in transplant recipients. Local recurrences and visceral spreading are not so uncommon and pose a major issue for quality of life and overall prognosis of these patients. Timely diagnosis is essential and may be challenging, since the accuracy of clinical diagnosis is modest; thus skin biopsy is an essential tool for appropriate management. In this review, we describe the most common types of skin cancer in renal transplant recipients, with a focus on pathogenic issues that account for the different epidemiology and clinical expression of these neoplasms in this population.

Stoff B, Salisbury C, Parker D, O’Reilly Zwald F (2010) Dermatopathology of skin cancer in solid organ transplant recipients. Transplant Rev 24(4):172–189CrossRef

Euvrard S, Kanikatis J, Claudy A (2003) Skin cancer after organ transplantation. N Engl J Med 348:1681–1691PubMedCrossRef

O’Reilly Zwald F, Brown M (2011) Skin cancer in organ transplant recipients: advances in therapy and management. J Am Acad Dermatol 65(2):253–614CrossRef

Kanitakis J, Euvrard S (2013) Donor-derived skin cancer in a kidney transplant recipient. Nat Rev Nephrol 9:702–703CrossRef

Rass K, Reichrath J (2008) UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 624:162–178CrossRef

Sheil AGR (2002) Organ transplantation and malignancy: inevitable linkage. Transplant Proc 34:2436–2437PubMedCrossRef

Hartevelt MM, Bouwes-Bavinck JN, Koote AM et al (1990) Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49:506–509PubMedCrossRef

Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122(2):464–472PubMedCentralPubMedCrossRef

Storey A, Thomas M, Kalita A et al (1998) Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 393:229–234PubMedCrossRef

10.

Zier K, Boulade-Ladame C et al (2012) Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 20:604–617CrossRef

11.

Gutierrez-Dalmau A, Revuelta I, Ferrer B et al (2010) Distinct immunohistochemical phenotype of non melanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 90:910–986CrossRef

12.

Andresen PA, Nymoen DA, Kjærheim K, Leivestad T, Helsing P (2013) Susceptibility to cutaneous squamous cell carcinoma in renal transplant recipients associates with genes regulating melanogenesis independent of their role in pigmentation. Biomark Cancer 5:41–47PubMedCentralPubMedCrossRef

13.

Wu X, Nguyen BC, Dziunycz P et al (2010) Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 465:368–372PubMedCentralPubMedCrossRef

14.

Maluccio M, Sharma V, Lagman M et al (2003) Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 76:597–602PubMedCrossRef

15.

Hojo M, Morimoto T, Maluccio M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530–534CrossRef

16.

Offman J, Opelz G, Doehler B et al (2004) Defective DNA mismatch repair in acute myeloid leukaemia/myelodysplastic syndrome after organ transplantation. Blood 104:822–828PubMedCrossRef

17.

Ponticelli C (2014) The pros and cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol 10:295–305PubMedCrossRef

18.

Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883–889PubMedCrossRef

19.

Cowen EW, Nguyen JC, Miller DD et al (2010) Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 62:31–37PubMedCentralPubMedCrossRef

20.

Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727–1730PubMed

21.

Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968PubMedCrossRef

22.

Euvrard S, Kanitakis J, Decullier E et al (2006) Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 81:1093–1100PubMedCrossRef

23.

Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335–339PubMed

24.

Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E et al (2007) Actinic keratoses: non-invasive diagnosis for field cancerization. Br J Dermatol 156:13–17PubMedCrossRef

25.

Reifenberger J, Wolter M, Knobbe CB et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152:43–51PubMedCrossRef

26.

Ziegler A, Leffell DJ, Kunala S et al (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216–4220PubMedCentralPubMedCrossRef

27.

Saldanha G, Ghura V, Potter L, Fletcher A (2004) Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 151:157–164PubMedCrossRef

28.

Sexton M, Jones DB, Maloney ME (1990) Histologic pattern analysis of basal cell carcinoma: study pf a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23:1118–1126PubMedCrossRef

29.

Rubin AI, Chen EH, Ratner D (2005) Basal-cell carcinoma. N Engl J Med 353:2262–2269PubMedCrossRef

30.

Lin JS, Eder M, Weinmann S (2011) Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 154:190–201PubMedCrossRef

31.

Seukeran DC, Newstead CG, Cunliffe WJ (1998) The compliance of renal transplant recipients with advice about sun protection measures. Br J Dermatol 138:301–303PubMedCrossRef

32.

Rose RF, Moniem K, Seukeran DC, Stables GI, Newstead CG (2005) Compliance of renal transplant recipients with advice about sun protection measures: completing the audit cycle. Transplant Proc. 37(10):4320–4322PubMedCrossRef

33.

Bahner JD, Bordeaux JS (2013) Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol 31:792–798PubMedCrossRef

34.

Bencini PL, Galimberti MG, Pellacani G, Longo C (2012) Application of photodynamic therapy combined with pre-illumination microneedling in the treatment of actinic keratosis in organ transplant recipients. Br J Dermatol 167(5):1193–1194PubMedCrossRef

35.

Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J (2013) Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 347:f6153PubMedCentralPubMedCrossRef

36.

Chen K, Craig JC, Shumack S (2005) Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 152:518–523PubMedCrossRef

37.

Karayannapoulou G, Euvrard S, Kanitakis J (2013) Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients. Anticancer Res 33(9):3711–3714

38.

Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339PubMedCrossRef

39.

Den Akker Hoogendijk-van JM, Harden PN, Hoitsma AJ et al (2013) Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 31:1317–1323CrossRef

40.

Alter M, Satzger I, Mattern A, Kapp A, Gutzmer R (2013) Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology 227(4):289–294PubMedCrossRef

41.

Sullivan AN, Bryant EA, Mark LA (2012) Malignant melanoma in transplant patients: a case report and review of the literature. Cutis 89(3):133–136PubMed

42.

Bilal M, Eason JD, Das K, Sylvestre PB, Dean AG, Vanatta JM (2013) Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting. Exp Clin Transplant 11(5):458–463CrossRef

43.

Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK (2002) Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 12(5):453–463PubMedCrossRef

44.

Russo AE, Torrisi E, Bevelacqua Y et al (2009) Melanoma: molecular pathogenesis and emerging target therapies. Int J Oncol 34(6):1481–1489PubMed

45.

Yajima I, Kumasaka MY, Thang ND et al (2012) RAS/RAF/MEK/ERK and PI3 K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012:354191PubMedCentralPubMedCrossRef

46.

Kanitakis J, Baldassini S, Lora V, Euvrard S (2010) BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol 20(2):167–171

47.

Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959CrossRef

48.

Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961PubMedCrossRef

49.

Le Mire L, Hollowood K, Gray D et al (2006) Melanoma in organ transplant recipients. Br J Dermatol 154:472–477PubMedCrossRef

50.

Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714PubMedCentralPubMedCrossRef

51.

da Rocha Dias S, Salmonson T, van Zwieten-Boot B et al (2013) The European Medicines Agency review of vemurafenib (Zelboraf^®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 49(7):1654–1661PubMedCrossRef

52.

Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488–496

53.

Della Vittoria Scarpati G, Fusciello C, Perri F et al (2014) Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7:203–209PubMedCentralPubMedCrossRef

54.

Kainthla R, Kim KB, Falchook GS (2013) Dabrafenib for treatment of BRAF-mutant melanoma. Pharmgenomics Pers Med 7:21–29PubMedCentralPubMed

55.

Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114PubMedCrossRef

56.

Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703PubMedCentralCrossRef

57.

Kadin ME, Hughey LC, Wood GS (2014) Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 70:374–376PubMedCrossRef

58.

Thomas BR, Whittaker S (2012) A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome. Skin Therapy Lett 17:5–9PubMed

59.

Seçkin D, Barete S, Euvrard S et al (2013) Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant 13:2146–2153PubMedCrossRef

60.

Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C (2012) Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 4:75–89PubMedCentral

61.

Jawed SI, wski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol 70:223.e1CrossRef

62.

Weberschock T, Strametz R, Lorenz M et al (2012) Interventions for mycosis fungoides. Cochrane Database Syst Rev 9:CD008946

63.

Penn I (1999) Kaposi’s sarcoma in transplant recipients. Transplantation 64:669–673CrossRef

64.

Sarid R, Kelpfish A, Schattner A (2002) Virology, pathogenic mechanisms and associated diseases of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc 77:941–949CrossRef

65.

Hengge UR, Ruzicka T, Tyring SK et al (2002) Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352PubMedCrossRef

66.

Jham BC, Montaner S (2010) The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor: lessons on dysregulated angiogenesis from a viral oncogene. J Cell Biochem 110:1–9PubMedCentralPubMed

67.

Dittmer DP, Damania B (2013) Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)–an update. Curr Opin Virol 3(3):238–244PubMedCentralPubMedCrossRef

68.

Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ (2008) HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 47(9):1209–1215PubMedCentralPubMedCrossRef

69.

Pellet C, Chevret S, Frances C et al (2002) Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in post transplantation Kaposi sarcoma. J Infect Dis 186:110–113PubMedCrossRef

70.

Andreoni M, Goletti D, Pezzotti P et al (2001) Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi’s sarcoma in renal and liver transplant recipients. J Infect 43:195–199PubMedCrossRef

71.

Harwood AR, Osoba D, Hofstader SL et al (1979) Kaposi’s sarcoma in recipients of renal transplants. Am J Med 67(5):759–765PubMedCrossRef

72.

Satter EK (2013) Kaposi sarcoma. Cutis 91(3):120–124PubMed

73.

Grayson W, Pantanowitz L (2008) Histologic variants of cutaneous Kaposi sarcoma. Diagn Patol 3:31CrossRef

74.

Schwartz RA (2004) Kaposi’s sarcoma: an update. J Surg Oncol 87:146–151PubMedCrossRef

75.

Jessop S (2006) HIV-associated Kaposi’s sarcoma. Dermatol Clin 24:509–520PubMedCrossRef

76.

Prinz Vavricka BM, Hofbauer GF, Dummer R et al (2012) Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. Clin Exp Dermatol 37:620–625PubMedCrossRef

77.

Dedicoat M, Vaithilingum M, Newton R (2003) Treatment of Kaposi’s sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev 3:CD003256PubMed

78.

Curatolo P, Quaglino P, Marenco F et al (2012) Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 19:192–198PubMedCrossRef

79.

Duman S, Toz H, Asci G et al (2002) Successful treatment of Kaposi’s sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 17:892–896PubMedCrossRef

80.

Otley CC, Berg D, Ulrich C et al (2006) Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Brit J Dermatol 154:395–400CrossRef

81.

Campistol JM, Gutierrez-Dalmau A, Torregrosa JV (2004) Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 77:760–762PubMedCrossRef

82.

Stallone G, Schena A, Infante B, Di Paolo S (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352:1317–1323PubMedCrossRef

83.

Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT (2011) Leflunomide with low-dose everolimus for treatment of Kaposi’s sarcoma in a renal allograft recipient. Nephrol Dial Transplant 26:3412–3415PubMedCrossRef

84.

Rockville Merkel Cell Carcinoma Group (2009) Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol 27:4021–4026CrossRef

85.

Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L (2014) Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 3:46–53PubMedCentralPubMedCrossRef

86.

Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a polyomavirus in human merkel cell carcinoma. Science 319:1096–1100PubMedCentralPubMedCrossRef

87.

Bhatia S, Afanasiev O, Nghiem P (2011) Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 13:488–497PubMedCrossRef

88.

Silvestris N, D’Elia F, Tarantino G, Lucarelli A (2000) Merkel cell carcinoma in a renal transplant patient. J Exp Clin Cancer Res 19:399–400PubMed

89.

Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Pukkala E, Sihto H, Joensuu H, Kyllönen L (2009) Mäkisalo incidence of merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant 24:3231–3235PubMedCrossRef

90.

Kurnatowska I, Zawiasa A, Narbutt J, Wagrowska-Danielewicz M, Stempien M, Nowicki M (2010) Merkel cell carcinoma in a kidney transplant patient: case report and update on management. Ann Transplant 15:66–70PubMed

91.

Friedlaender MM, Rubinger D, Rosenbaum E, Amir G, Siguencia E (2002) Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 73:1849–1850PubMedCrossRef

Titel: Skin cancer in kidney transplant recipients
verfasst von: Claudio Ponticelli
David Cucchiari
PierLuca Bencini
Publikationsdatum: 01.08.2014
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 4/2014
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-014-0098-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Comment on Suzuki et al.: “Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy”

Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) and kidney diseases: HCaRG accelerates tubular repair

Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy: response to comment

Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients

Erratum to: Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?